The Expression and Prognostic Value of TERF2 in Head and Neck Squamous Cell Carcinoma

Authors

  • Junfeng Tang School of Laboratory Medicine, North Sichuan Medical College, Nanchong 637000, China
  • Yi Chen School of Laboratory Medicine, North Sichuan Medical College, Nanchong 637000, China
  • Yujie Luo School of Laboratory Medicine, North Sichuan Medical College, Nanchong 637000, China
  • Xiaowu Zhong School of Laboratory Medicine, North Sichuan Medical College, Nanchong 637000, China; Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; Translational Medicine Research Center, North Sichuan Medical College, Nanchong 637000, China

DOI:

https://doi.org/10.53469/jcmp.2024.06(11).42

Keywords:

TERF2, Head and neck squamous cell carcinoma, Bioinformatics, Prognosis

Abstract

TERF2 is identified as a potential biomarker in many cancers. However, its role in Head and neck squamous cell carcinoma (HNSC) remains poorly understood. TERF2 levels among HNSC patients were studied by TIMER and UALCAN. The overall survival and clinical features of HNSC patients were analyzed by Kaplan-Meier (KM) method. Potential relation of TERF2 with HNSC was explored by using cBioPortal, MEXPRESS and TIMER. Meanwhile, TERF2-related genes were subject to GO and KEGG analyses. Higher TERF2 expression predicted a poor prognosis in HNSC patients. In addition, TERF2 was associated with genetic alterations, methylation and immune infiltration in HNSC. TERF2 was crucially involved in biological processes such as protein processing in the endoplasmic reticulum, ubiquitin-mediated proteolysis, insulin signaling pathway, and thyroid hormone signaling pathway and so on. The expression of TERF2 was closely related to HNSC survival. This probably provided new visions for TERF2 as a possible diagnostic and prognostic indicator for HNSC.

References

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.

Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stageepithelial carcinomas[J]. Biochim Biophys Acta, 2009, 1796(2): 309-14.

Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15(9):994-1001.

Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011 Dec;21(6):349-53.

Broccoli D, Smogorzewska A, Chong L, et al. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet. 1997 Oct;17(2):231-5.

Yang D, Xiong Y, Kim H, et al. Human telomeric proteins occupy selective interstitial sites. Cell Res. 2011 Jul;21(7):1013-27.

Biroccio A, Cherfils-Vicini J, Augereau A, et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol. 2013;15(7):818–28.

Ozden S, Tiber PM, Ozgen Z, et al. Expression of TRF2 and its prognostic relevance in advanced stage cervical cancer patients. Biol Res. 2014 Nov 25;47(1):61.

Lin X, Gu J, Lu C, et al. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Oct 1;12(19):5720-5.

Benhamou Y, Picco V, Raybaud H, et al. Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma. Oncotarget. 2016 Jul 12;7(28):44236-44251.

Wang Z, Wu X. Abnormal function of telomere protein TRF2 induces cell mutation and the effects of environmental tumorpromoting factors (Review). Oncol Rep. 2021 Aug;46(2):184.

McDaniel LD, Schultz RA, Friedberg EC. TRF2-XPF: caught in the middle; beginnings from the end. DNA Repair (Amst). 2006 Jul 13;5(7):868-72. doi: 10.1016/j.dnarep.2006.03.012. Epub 2006 Jun 9.

Dong W, Shen R, Wang Q, et al. Sp1 upregulates expression of TRF2 and TRF2 inhibition reduces tumorigenesis in human colorectal carcinoma cells. Cancer Biol Ther. 2009;8(22):2166–74.

Diehl MC, Idowu MO, Kimmelshue KN, et al. Elevated TRF2 in advanced breast cancers with short telomeres. Breast Cancer Res Treat. 2011;127(3):623–30.

Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240.

Matsutani N, Yokozaki H, Tahara E, et al. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol. 2001 Sep;19(3):507-12.

Oh BK, Kim YJ, Park C, et al. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol. 2005 Jan;166(1):73-80.

Blanco R, Muñoz P, Flores JM, et al. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev. 2007 Jan 15;21(2):206-20.

Luo Z, Feng X, Wang H, et al. Mir-23a induces telomere dysfunction and cellular senescence by inhibiting TRF2 expression. Aging Cell. 2015 Jun;14(3):391-9.

Matsutani N, Yokozaki H, Tahara E, et al. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol. 2001 Sep;19(3):507-12.

Han S, Oh JS, Lee HS, et al. Genetic alterations associated with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in head and neck squamous cell carcinoma. Transl Oncol. 2021 Feb;14(2):100988.

Ghafarpour V, Khansari M, Banaei-Moghaddam AM, et al. DNA methylation association with stage progression of head and neck squamous cell carcinoma. Comput Biol Med. 2021 Jul;134:104473.

Leitheiser M, Capper D, Seegerer P, et al. Machine learning models predict the primary sites of head and neck squamous cell carcinoma metastases based on DNA methylation. J Pathol. 2022 Apr;256(4):378-387.

Luo Z, Liu W, Sun P, et al. Pan-cancer analyses reveal regulation and clinical outcome association of the shelterin complex in cancer. Brief Bioinform. 2021 Sep 2;22(5):bbaa441.

Zhang Y, Lin A, Li Y, et al. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Front Cell Dev Biol. 2020 Dec 9;8:608969.

Zhang X, Shi M, Chen T, et al. Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020 Aug 29;22:298-309.

Broccoli D, Smogorzewska A, Chong L, et al. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet. 1997 Oct;17(2):231-5.

Rizzo A, Iachettini S, Salvati E, et al. SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage. Nucleic Acids Res. 2017 Feb 28;45(4):1820-1834.

Kugler SJ, Nagel AC. putzig is required for cell proliferation and regulates notch activity in Drosophila. Mol Biol Cell. 2007 Oct;18(10):3733-40.

Zizza P, Dinami R, Porru M, et al. TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. Nucleic Acids Res. 2019 Apr 23;47(7):3365-3382.

Downloads

Published

2024-11-28

How to Cite

Tang, J., Chen, Y., Luo, Y., & Zhong, X. (2024). The Expression and Prognostic Value of TERF2 in Head and Neck Squamous Cell Carcinoma. Journal of Contemporary Medical Practice, 6(11), 212–219. https://doi.org/10.53469/jcmp.2024.06(11).42

Issue

Vol. 6 No. 11 (2024): JCMP-Volume 6 Issue 11

Section

Articles

License

Copyright (c) 2024 Junfeng Tang, Yi Chen, Yujie Luo, Xiaowu Zhong

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.